GlassScriptPhysician profile
Michael Charles Mareska
NPI 1538130778
$1,901.49
in general payments reported to CMS, 2019-2025
33 companies · $311 in 2025
The $311 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,385 · 2022: $40.83 · 2023: $133 · 2024: $31.93 · 2025: $311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $475.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $188.55 | 2019 | |
| Amgen INC. | $184.62 | 2019-2025 | Uplizna |
| Novartis Pharmaceuticals Corporation | $175.64 | 2019-2025 | |
| Genzyme Corporation | $153.32 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $145.26 | 2019 | |
| Axsome Therapeutics, INC. | $95.58 | 2025 | Symbravo |
| Emd Serono, INC. | $76.91 | 2019 | |
| Abbvie INC. | $75.98 | 2022-2025 | |
| Acadia Pharmaceuticals INC | $71.06 | 2019 | |
| Alexion Pharmaceuticals, INC. | $51.65 | 2019 | |
| Grifols USA, LLC | $51.30 | 2019-2025 | Gamunex-C |
| Eisai INC. | $49.73 | 2019 | |
| Ucb, INC. | $49.30 | 2019 | |
| Tg Therapeutics, INC. | $48.71 | 2025 | |
| Assertio Therapeutics, INC. | $42.89 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $42.28 | 2019 | |
| Acorda Therapeutics, INC | $37.90 | 2019 | |
| Sunovion Pharmaceuticals INC. | $37.84 | 2019 | |
| Amneal Pharmaceuticals LLC | $37.45 | 2019 | |
| Mdd US Operations, LLC | $30.65 | 2019 | |
| Genentech USA, INC. | $29.80 | 2019 | |
| Lilly USA, LLC | $28.47 | 2019-2024 | Kisunla |
| Sk Life Science, INC. | $28.25 | 2025 | |
| Argenx US, INC. | $27.98 | 2025 | Vyvgart |
| Avanir Pharmaceuticals, INC. | $23.58 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.14 | 2019 | |
| Upsher-Smith Laboratories LLC | $20.17 | 2019 | |
| Aquestive Therapeutics, INC. | $15.07 | 2019 | |
| Pfizer INC. | $14.63 | 2019 | |
| Promius Pharma LLC | $12.37 | 2019 | |
| Impel Pharmaceuticals INC. | $12.16 | 2022 | |
| Livanova USA, INC. | $11.12 | 2019 | |
| Dynasplint Systems INC. | $10.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mareska listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.